Silvia Marsoni
Silvia Marsoni
Verified email at ifom.eu
TitleCited byYear
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
DJ Sargent, S Marsoni, G Monges, SN Thibodeau, R Labianca, ...
Journal of Clinical Oncology 28 (20), 3219, 2010
10292010
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corą, ...
Cancer discovery 1 (6), 508-523, 2011
5892011
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795, 2015
5092015
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
MC Garassino, O Martelli, M Broggini, G Farina, S Veronese, E Rulli, ...
The lancet oncology 14 (10), 981-988, 2013
4782013
Etoposide (VP-16–213) Current Status of an Active Anticancer Drug
PJ O'Dwyer, B Leyland-Jones, MT Alonso, S Marsoni, RE Wittes
New England Journal of Medicine 312 (11), 692-700, 1985
4411985
Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial
P Ghezzi, S Magnanini, M Rinaldini, F Berardi, G Di Biagio, F Testare, ...
Jama 271 (20), 1587-1592, 1994
4361994
Integrating liquid biopsies into the management of cancer
G Siravegna, S Marsoni, S Siena, A Bardelli
Nature reviews Clinical oncology 14 (9), 531, 2017
4282017
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
FA Sinicrope, NR Foster, SN Thibodeau, S Marsoni, G Monges, ...
Journal of the National Cancer Institute 103 (11), 863-875, 2011
3922011
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
FA Sinicrope, NR Foster, SN Thibodeau, S Marsoni, G Monges, ...
Journal of the National Cancer Institute 103 (11), 863-875, 2011
3922011
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
3162016
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials
K Aabo, M Adams, P Adnitt, DS Alberts, A Athanazziou, V Barley, DR Bell, ...
British journal of cancer 78 (11), 1479, 1998
2271998
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ...
Nature 526 (7572), 263, 2015
2262015
Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)
G Bolis, N Colombo, S Pecorelli, V Torri, S Marsoni, C Bonazzi, S Chiari, ...
Annals of oncology 6 (9), 887-893, 1995
1981995
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
C Sessa, F De Braud, A Perotti, J Bauer, G Curigliano, C Noberasco, ...
Journal of Clinical Oncology 23 (9), 1867-1874, 2005
1852005
Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG …
B Langer, H Bleiberg, R Labianca, L Shepherd, D Nitti, S Marsoni, D Tu, ...
Proc Am Soc Clin Oncol 21 (S1), 149a, 2002
1692002
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin
C Mangioni, G Bolis, S Pecorelli, K Bragman, A Epis, G Favalli, ...
JNCI: Journal of the National Cancer Institute 81 (19), 1464-1471, 1989
1601989
Therapeutic response in phase I trials of antineoplastic agents.
E Estey, D Hoth, R Simon, S Marsoni, B Leyland-Jones, R Wittes
Cancer treatment reports 70 (9), 1105-1115, 1986
1571986
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
G Migliardi, F Sassi, D Torti, F Galimi, ER Zanella, M Buscarino, D Ribero, ...
Clinical Cancer Research 18 (9), 2515-2525, 2012
1422012
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled …
DJ Sargent, S Marsoni, SN Thibodeau, R Labianca, SR Hamilton, V Torri, ...
Journal of Clinical Oncology 26 (15_suppl), 4008-4008, 2008
1332008
Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a …
P Olmi, S Crispino, C Fallai, V Torri, F Rossi, A Bolner, M Amichetti, ...
International Journal of Radiation Oncology* Biology* Physics 55 (1), 78-92, 2003
1312003
The system can't perform the operation now. Try again later.
Articles 1–20